Previous 10 | Next 10 |
Hologic (NASDAQ: HOLX ) fiscal Q2 results : More news on: Hologic, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Hologic (NASDAQ: HOLX ): Q2 Non-GAAP EPS of $0.57 in-line; GAAP EPS of $0.36 beats by $0.04 . More news on: Hologic, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Company to Produce at Least One Million Tests a Week to Run on More than 1,000 Panther Instruments Installed in All 50 States -- -- Significant Assay Manufacturing Capacity Plus Large Installed Base of Fully Automated Systems Expected to Dramatically Increase Coronavirus Testing Cap...
– Revenue of $756.1 Million Declines 7.6% due to Cynosure Divestiture, 7.1% in Constant Currency – – Organic Revenue Increases 0.5%, 1.1% in Constant Currency – – Company Posts GAAP Diluted EPS of $0.36, Non-GAAP Diluted EPS of $0.57 – ...
New York City, NY: April 17, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Breast Tissue Markers Market in Global Industry: 2020 Research and New Innovations in Pharmaceuticals and Healthcare Sector. The prime objective of the report is to ...
Clearly no vaccine has been found… Most experts are giving at least a year for a vaccine to be found, tested and released. Then we have to get 90% of the population that has no natural antibodies to actually get the vaccine. This piece is a continuation of my Sunday note. In that ...
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2020 on Wednesday, April 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Tim...
Hologic (NASDAQ: HOLX ) is withdrawing its Q2 and FY 2020 guidance, in response to COVID-19 pandemic. More news on: Hologic, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
New York City, NY: April 06, 2020 – Published via (Wired Release) – Recent Research and Future Market Potential of Cervical Cancer Diagnostic Test Market in Global Industry: 2020 Research and New Innovations in Medical Devices Sector. The prime objective of the report is to offer...
-- Revenue of $756.1 Million Declines 7.6% due to Cynosure Divestiture, 7.1% in Constant Currency -- -- Excluding Acquisitions and Divestitures, Revenue Increases 0.5%, 1.1% in Constant Currency -- Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its second...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...